Precision Epigenomics Named 2026 AZBio Fast Lane Award Honoree

Tucson-based biotechnology company recognized for clinical, commercial, laboratory, and strategic milestones advancing early cancer detection.

TUCSON , AZ, UNITED STATES, September 21, 2026 /EINPresswire.com/ — Precision Epigenomics Inc., an Arizona biotechnology company developing innovative liquid biopsy technologies for the early detection of cancer, has been named a 2026 AZBio Fast Lane Award honoree by the Arizona Bioindustry Association (AZBio).

The AZBio Fast Lane Award recognizes Arizona bioscience companies that have achieved significant milestones and demonstrated exceptional momentum over the preceding 18 months. Precision Epigenomics will be formally honored at the 23rd Annual AZBio Awards on October 7, 2026, at the Phoenix Convention Center.

The recognition comes at a pivotal time for Precision Epigenomics as the Tucson-based company advances the commercialization of EPISEEK^®, its multi-cancer early detection (MCED) blood test, while expanding clinical validation, laboratory capabilities, strategic partnerships, and access to cancer screening for high-risk populations.

“Receiving the AZBio Fast Lane Award is a tremendous honor and an important validation of the progress our team has made,” said Dr. Mark Nelson, CEO of Precision Epigenomics. “Over the past 18 months, we have moved EPISEEK from an innovative scientific concept to a clinically deployed cancer detection platform. This recognition reflects the dedication of our scientific, clinical, laboratory, and commercial teams and the support of our partners, investors, and the Arizona bioscience community.”

Advancing a New Approach to Cancer Detection
At the center of Precision Epigenomics’ technology platform is EPISEEK, a blood-based multi-cancer early detection test designed to identify cancer-associated epigenetic changes in cell-free DNA. Unlike conventional screening approaches that focus on only a few cancers, EPISEEK is designed to analyze methylation patterns associated with multiple cancer types from a single blood sample. The company reports that its technology can identify signals associated with more than 70 cancer types and is currently the only MCED test on the market detecting brain cancer.

Building a Clinical-Grade Diagnostic Platform in Arizona
A major milestone in the company’s development has been the establishment and expansion of its laboratory operations in Tucson. Precision Epigenomics operates a CLIA-certified, CAP-accredited molecular pathology laboratory, providing the infrastructure necessary to support clinical testing and continued development of its liquid biopsy platform, as well as additional molecular diagnostic applications targeting cancers.

Bringing Early Detection to First Responders
Precision Epigenomics is also addressing one of the populations with a particularly strong need for earlier cancer detection: first responders. Firefighters and other public safety professionals have an increased risk of developing cancer. Recognizing the need for improved cancer surveillance in these populations, Precision Epigenomics has established partnerships designed to bring EPISEEK directly into occupational health programs. The company supports cancer screening initiatives involving firefighters across the United States.

“Our mission is not simply to develop another laboratory test,” said Dr. Richard Bernert, COO. “It is to change the way cancer is detected—moving from a model that often waits for symptoms to appear toward one that identifies molecular evidence of disease as early as possible. First responders are an important starting point because they represent a population with significant occupational cancer concerns and a strong commitment to preventive health.”

From University of Arizona Spinout to Emerging Bioscience Company
Precision Epigenomics was founded as a spinout from the University of Arizona, translating academic research in cancer epigenetics into commercial diagnostic technologies. The company has progressed from laboratory development into clinical testing and commercialization while continuing to pursue additional clinical validation and market access opportunities. Its recent progress includes expanding its provider network, establishing strategic commercial partnerships, advancing clinical studies, strengthening its laboratory infrastructure, and pursuing regulatory and reimbursement pathways for its diagnostic technologies. The company is also developing next-generation versions of its EPISEEK platform intended to further improve diagnostic performance and broaden clinical applications.

Accelerating the Future of Precision Oncology
The AZBio Fast Lane Award places Precision Epigenomics among a select group of Arizona bioscience companies recognized for accelerating innovation and achieving meaningful milestones. For Precision Epigenomics, the award represents both recognition of the company’s progress and a milestone on the path toward a larger vision: making molecular cancer detection more accessible, earlier, and increasingly integrated into routine healthcare.

“Arizona has built one of the nation’s most dynamic bioscience ecosystems, and we are proud to be part of it,” Nelson said. “We are grateful to AZBio for recognizing Precision Epigenomics and, more importantly, for recognizing the potential impact that earlier cancer detection can have on patients, families, employers, and healthcare systems. We believe the next phase of our journey is going to be even more significant.”

For more information, please contact Jannalee Johnson at jjohnson@Precision-Epigenomics.com.

About Precision Epigenomics
Precision Epigenomics Inc. is a Tucson, Arizona-based biotechnology company focused on developing innovative molecular diagnostic technologies for the early detection of cancer. The company’s flagship EPISEEK^® platform uses epigenetic signatures in circulating DNA to identify molecular signals associated with cancer. Precision Epigenomics operates a CLIA-certified and CAP-accredited molecular pathology laboratory and is developing a growing pipeline of liquid biopsy applications designed to improve cancer detection and diagnostic decision-making.

Regulatory and Forward-Looking Statements Disclaimer
This press release contains forward-looking statements within the meaning of applicable securities laws. These statements included but are not limited to product performance and the anticipated benefits of the EPISEEK-MCED test. Forward looking statements are based on current assumptions and are subject to change that may cause actual results to differ materially from those expressed or implied. These risks include, among others, regulatory developments, competitive pressures, operational challenges, and economic conditions.

Richard Bernert
Precision Epigenomics Inc.
+1-520-372-7522

Richard Bernert, MD, FCAP
Precision Epigenomics Inc.
+1 (520) 372-7522
email us here
Visit us on social media:
LinkedIn
Facebook
YouTube
X

Media gallery